Metropolitan Life Insurance Company (MetLife)’s Prime Medicine PRME Stock Holding History

Metropolitan Life Insurance Company (MetLife)’s Portfolio PRME Stock Details PRME Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q2	–	Sell	-2,203	Closed	-$15.4K	–	1603
2024 Q1	$15.4K	Hold	2,203	–	–	﹤0.01%	1976
2023 Q4	$19.5K	Hold	2,203	–	–	﹤0.01%	1933
2023 Q3	$21K	Hold	2,203	–	–	﹤0.01%	1870
2023 Q2	$32.3K	Buy	2,203 +1,485	+207%	+$20.7K	﹤0.01%	1677
2023 Q1	$8.83K	Hold	718	–	–	﹤0.01%	2199
2022 Q4	$13.3K	Buy	+718	New	+$13K	﹤0.01%	2180

Other funds holding PRME

Alphabet Inc Mountain View, California $99.1B AUM 124.46% 1-Year Est. Return

AIM

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return

NAMA

Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return

Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return

MWG Management Road Town, Tortola, British Virgin Islands $81.3M AUM 2.28% 1-Year Est. Return

Metropolitan Life Insurance Company (MetLife)'s PRME Position: Q2 2024 in Review

Metropolitan Life Insurance Company (MetLife) sold out of Prime Medicine (PRME) in Q2 2024, closing a stake of 2,203 shares — an estimated $15.4K sold.

Metropolitan Life Insurance Company (MetLife) first reported a position in PRME in Q4 2022 and held it in 6 quarters. The position peaked at $32.3K in Q2 2023. 122 funds tracked by Wall St. Rank hold PRME as of Q2 2024.

Metropolitan Life Insurance Company (MetLife) reported no remaining Prime Medicine position as of Q2 2024 after selling out during the quarter.
Metropolitan Life Insurance Company (MetLife) sold 2,203 Prime Medicine shares in Q2 2024, an estimated $15.4K.
Metropolitan Life Insurance Company (MetLife) first reported a position in Prime Medicine in Q4 2022 and held it in 6 quarters.
Metropolitan Life Insurance Company (MetLife)'s Prime Medicine position peaked at $32.3K in Q2 2023.
122 funds tracked by Wall St. Rank held Prime Medicine as of Q2 2024.

Based on Metropolitan Life Insurance Company (MetLife)'s 13F filing for Q2 2024, filed 13 Aug 2024.